Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Leases (2016 - 2019)

Enanta Pharmaceuticals' Capital Leases history spans 5 years, with the latest figure at $200000.0 for Q3 2019.

  • For Q3 2019, Capital Leases fell 31.74% year-over-year to $200000.0; the TTM value through Sep 2019 reached $200000.0, down 31.74%, while the annual FY2019 figure was $200000.0, 31.74% down from the prior year.
  • Capital Leases reached $200000.0 in Q3 2019 per ENTA's latest filing, down from $224000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $529000.0 in Q3 2015 to a low of $175000.0 in Q2 2015.
  • Average Capital Leases over 5 years is $364166.7, with a median of $368500.0 recorded in 2017.
  • Peak YoY movement for Capital Leases: skyrocketed 173.14% in 2016, then crashed 31.74% in 2019.
  • A 5-year view of Capital Leases shows it stood at $513000.0 in 2015, then dropped by 14.23% to $440000.0 in 2016, then fell by 18.64% to $358000.0 in 2017, then fell by 24.3% to $271000.0 in 2018, then decreased by 26.2% to $200000.0 in 2019.
  • Per Business Quant, the three most recent readings for ENTA's Capital Leases are $200000.0 (Q3 2019), $224000.0 (Q2 2019), and $249000.0 (Q1 2019).